*The English version of this report will be available in a due course.

On May 7, 2025, Health and Global Policy Institute (HGPI) has released a new set of policy recommendations, “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan.”

These recommendations are being released as a part of HGPI’s recently launched “HGPI Expert Policy Advocacy Platform,” which will facilitate the creation and promotion of policy recommendations by HGPI fellows and others associated with the Institute. Through this platform, policy recommendations developed by HGPI Fellows and others are scrutinized and approved by a review committee within HGPI. Upon their approval, HGPI commits to issuing and advocating for the proposals. It is hoped that this new platform will produce a wide variety of both feasible and creative solutions to today’s pressing health policy issues.

Dr. Ataru Igarashi, an HGPI Fellow, has created a set of policy recommendations entitled, “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan.”